Market revenue in 2023 | USD 2,350.9 million |
Market revenue in 2030 | USD 3,092.2 million |
Growth rate | 4% (CAGR from 2023 to 2030) |
Largest segment | Infectious diseases |
Fastest growing segment | Oncology |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Oncology, Prenatal Testing, Endocrinology, Other Applications, Hematology, Infectious Diseases |
Key market players worldwide | Roche, Abbott Laboratories, Qiagen NV, Bayer AG, Nova Biomedical, Danaher Corp, Nipro Corp, Bio-Rad Laboratories Inc, Agilent Technologies Inc, BioMerieux SA, OraSure Technologies Inc, Abaxis |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to point-of-care molecular diagnostics market will help companies and investors design strategic landscapes.
Infectious diseases was the largest segment with a revenue share of 93.46% in 2023. Horizon Databook has segmented the North America point-of-care molecular diagnostics market based on oncology, prenatal testing, endocrinology, other applications, hematology, infectious diseases covering the revenue growth of each sub-segment from 2018 to 2030.
North America was the largest regional market for revenue generation in 2022. The growing geriatric population and higher healthcare expenditure are key factors contributing to its largest share. In North America, Point-of-Care (POC) molecular diagnostics is witnessing a significant trend of increased adoption and integration into healthcare practices.
The region's well-established healthcare infrastructure and technological advancements have paved the way for the rapid implementation of POC molecular diagnostic technologies. The trend is driven by the growing demand for faster and more accurate diagnostics, especially concerning infectious diseases like COVID-19. POC molecular tests offer the advantage of real-time results, enabling timely treatment decisions and patient management.
In addition, advancements in miniaturization, AI integration, and connectivity are further enhancing the efficiency and accessibility of POC molecular diagnostics, making them a critical component of healthcare systems in North America.
Horizon Databook provides a detailed overview of continent-level data and insights on the North America point-of-care molecular diagnostics market , including forecasts for subscribers. This continent databook contains high-level insights into North America point-of-care molecular diagnostics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account